The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•14 April 2026•

1 min read

Niagen Bioscience Partners with USP to Establish First NRCl Quality Monograph

A world map in golden tones with overlaid financial charts showing a downward trend, a large blue arrow pointing down, and falling circuit boards and text. Two screens display NASDAQ data.

Key Facts

1Niagen Bioscience announced the publication of the first-ever USP monograph for Nicotinamide Riboside Chloride (NRCl).

Niagen Bioscience (NAGE) has announced a significant regulatory milestone with the publication of the first-ever USP monograph for Nicotinamide Riboside Chloride (NRCl). This substance is the patented form utilized in the company's flagship ingredient, Niagen®. The collaboration with the United States Pharmacopeia (USP) establishes formal quality and purity standards, providing critical scientific validation for the ingredient. This move is expected to strengthen the company's market position within the dietary supplement and healthy aging sectors. By securing this monograph, Niagen Bioscience enhances consumer trust and facilitates broader B2B adoption. Analysts view this development as a positive driver for long-term revenue growth and regulatory stability. The establishment of these standards underscores the company's commitment to pharmaceutical-grade quality in the biotech market.